Try, Try, Try Again

Bucindolol, a beta-blocker that never made it to the market because a patient study showed it did not reduce the risk of death due to high blood pressure and heart failure, may be making a comeback. According to the Wall Street Journal, researchers report that heart failure patients with a specific genetic mutation given the drug were 48 percent less likely to die of heart-related problems and 44 percent less likely to be hospitalized, as compared to those given placebo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.